Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | CETP | P11597 | 2/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5471889 | 0.74 | TRPV1 (0.45) | CETPMTNR1AMTNR1B | |
| SCHEMBL5474014 | 0.73 | KDM4C (0.40) | KMT2AMEN1TDP1 | |
| SCHEMBL5478158 | 0.71 | TAS1R3 (0.37) | TAS1R3TAS1R1TAS1R2SLC18A3 | |
| SCHEMBL5477889 | 0.71 | MTNR1A (0.38) | TAS1R3TAS1R1TAS1R2CETPMTNR1A | |
| SCHEMBL4972049 | 0.71 | HTR2C (0.40) | TAS1R3TAS1R1TAS1R2HTR2C | |
| SCHEMBL30130746 | 0.71 | HTR2C (0.40) | TAS1R3TAS1R1TAS1R2HTR2C | |
| SCHEMBL5471348 | 0.70 | TAS1R3 (0.30) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5475432 | 0.70 | HSD11B1 (0.34) | TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5471002 | 0.67 | SIGMAR1 (0.50) | — | |
| SCHEMBL5174956 | 0.67 | TAS1R3 (0.36) | TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, CXCL8, MPO | KMT2A 4398/4885MEN1 4594/4885TAS1R3 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.